Celcuity's (CELC) "Market Outperform" Rating Reiterated at Citizens Jmp

Key Points

• Citizens Jmp reiterated its “Market Outperform” rating on Celcuity and set a $177 price target, implying roughly 92% upside from the prior close.
• Analyst sentiment remains positive overall: ten analysts rate Celcuity a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and an average price target of $153.64.
• Celcuity reported quarterly adjusted losses of $1.44 per share, missing the $1.16 consensus estimate; shares opened at $92, while institutional investors own 63.33% of the company.

Celcuity (NASDAQ:CELC - Get Free Report)'s stock had its "market outperform" rating restated by stock analysts at Citizens Jmp in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $177.00 price target on the stock. Citizens Jmp's target price would indicate a potential upside of 92.39% from the stock's previous close.

CELC has been the subject of several other research reports. Stifel Nicolaus cut their price objective on Celcuity from $175.00 to $150.00 and set a "buy" rating for the company in a report on Friday. HC Wainwright reaffirmed a "buy" rating and issued a $155.00 target price on shares of Celcuity in a research note on Friday. Citigroup reissued a "market outperform" rating on shares of Celcuity in a research note on Monday. Needham & Company LLC cut their price objective on shares of Celcuity from $157.00 to $140.00 and set a "buy" rating for the company in a research note on Friday. Finally, Guggenheim reissued a "buy" rating on shares of Celcuity in a research note on Monday. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $153.64.

Celcuity Stock Performance

Shares of Celcuity stock opened at $92.00 on Monday. Celcuity has a 12-month low of $44.42 and a 12-month high of $151.02. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04. The company has a market capitalization of $4.49 billion, a P/E ratio of -21.40 and a beta of 0.21. The stock has a fifty day simple moving average of $93.88 and a 200 day simple moving average of $108.41.

Celcuity (NASDAQ:CELC - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.16) by ($0.28). On average, sell-side analysts anticipate that Celcuity will post -3.76 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celcuity

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Hsbc Holdings PLC purchased a new stake in Celcuity during the 4th quarter valued at about $1,058,000. California State Teachers Retirement System raised its holdings in Celcuity by 91.2% in the first quarter. California State Teachers Retirement System now owns 25,580 shares of the company's stock worth $2,920,000 after buying an additional 12,201 shares during the last quarter. Jennison Associates LLC purchased a new stake in shares of Celcuity during the fourth quarter valued at approximately $22,911,000. Geode Capital Management LLC increased its position in shares of Celcuity by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 830,684 shares of the company's stock valued at $82,872,000 after acquiring an additional 64,213 shares in the last quarter. Finally, TD Asset Management Inc raised its holdings in Celcuity by 34.0% in the 4th quarter. TD Asset Management Inc now owns 97,526 shares of the company's stock worth $9,727,000 after acquiring an additional 24,730 shares during the last quarter. Institutional investors own 63.33% of the company's stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source